Arthritis research & therapy · 2025
Investigation of serum biomarkers in rheumatoid and psoriatic arthritis patients for disease-specific signatures.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Veale James D, Gorman Áine, Veale Douglas J, Fearon Ursula, Orr Carl, Marzaioli Viviana
Аннотация
BACKGROUND: Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA) are systemic auto-immune diseases of unknown aetiology that lead to systemic inflammation and synovial joint destruction. Identification of specific serum proteins that selectively regulate these diseases, or which precede disease development could have great potential as disease biomarkers and predictors.
METHODS: Serum levels of C-reactive protein (CRP), sICAM-1, sVCAM-1, Serum amyloid A (SAA), Matrix metalloproteinases (MMPs 1, 3 and 9) and metabolic markers: Active Glucose-dependent Insulinotropic polypeptide (GIP), active Glucagon-like peptide-1 (GLP-1), C-Peptide, Glucagon, Insulin, Leptin, Pancreatic Polypeptide (PP) were measured by Meso Scale Discovery (MSD) multiplex analysis assay.
RESULTS: Serum levels of sICAM-1, MMP1, MMP3, PP, c-Peptide, CRP and SAA were specifically upregulated in RA, but not in PsA disease, displaying high sensitivity (ROC curves). In the early phase of the disease, these markers may be suitable for discriminating RA from PsA patients. Differences in sex, BMI, and disease activity were observed. This is the first study which directly compare serum metabolic markers between diseases and identifies specific disease signatures between RA and PsA. In addition, this study identified that CRP, SAA, GLP-1, GIP-1, Leptin and PP serum protein precede disease onset, as they are already altered in the serum of 'individuals at risk' of developing RA. Of these, CRP, SAA, Leptin and PP might predict IAR conversion to RA+, thus making them suitable candidates for disease prediction.
CONCLUSIONS: Altogether, this study identifies selective serum markers associated with RA and PsA, which are pathotype-specific and are predictors of RA disease onset.
METHODS: Serum levels of C-reactive protein (CRP), sICAM-1, sVCAM-1, Serum amyloid A (SAA), Matrix metalloproteinases (MMPs 1, 3 and 9) and metabolic markers: Active Glucose-dependent Insulinotropic polypeptide (GIP), active Glucagon-like peptide-1 (GLP-1), C-Peptide, Glucagon, Insulin, Leptin, Pancreatic Polypeptide (PP) were measured by Meso Scale Discovery (MSD) multiplex analysis assay.
RESULTS: Serum levels of sICAM-1, MMP1, MMP3, PP, c-Peptide, CRP and SAA were specifically upregulated in RA, but not in PsA disease, displaying high sensitivity (ROC curves). In the early phase of the disease, these markers may be suitable for discriminating RA from PsA patients. Differences in sex, BMI, and disease activity were observed. This is the first study which directly compare serum metabolic markers between diseases and identifies specific disease signatures between RA and PsA. In addition, this study identified that CRP, SAA, GLP-1, GIP-1, Leptin and PP serum protein precede disease onset, as they are already altered in the serum of 'individuals at risk' of developing RA. Of these, CRP, SAA, Leptin and PP might predict IAR conversion to RA+, thus making them suitable candidates for disease prediction.
CONCLUSIONS: Altogether, this study identifies selective serum markers associated with RA and PsA, which are pathotype-specific and are predictors of RA disease onset.